ALKS 4230

Drug Profile

ALKS 4230

Alternative Names: ALKS-4230; RDB 1450; RDB-1419

Latest Information Update: 07 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alkermes plc
  • Class Antineoplastics; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 Apr 2018 Alkermes plans a clinical proof of concept, dose escalation and dose expansion trial for Solid tumours in second half of 2018 (Alkermes pipeline, April 2018)
  • 27 Mar 2017 Pharmacodynamics data from preclinical studies in Cancer released by Alkermes
  • 21 Feb 2017 Alkermes has patent protection for ALKS 4230 in USA (Alkermes plc 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top